triazolam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 2729 28911-01-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triazolam
  • U-33,030
  • U 33,030
  • U33,030
A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
  • Molecular weight: 343.21
  • Formula: C17H12Cl2N4
  • CLOGP: 2.62
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 43.07
  • ALOGS: -4.27
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.25 mg O
0.20 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.02 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 44 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.58 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 15, 1982 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 592.22 15.16 196 9009 19683 50576236
Drug abuse 386.24 15.16 197 9008 59649 50536270
Overdose 190.23 15.16 152 9053 99575 50496344
Suicide attempt 177.87 15.16 113 9092 51619 50544300
Intentional self-injury 160.20 15.16 80 9125 23032 50572887
Intentional overdose 109.99 15.16 91 9114 62413 50533506
Loss of consciousness 80.54 15.16 97 9108 104256 50491663
Coma 80.19 15.16 73 9132 56806 50539113
Altered state of consciousness 75.54 15.16 48 9157 21862 50574057
Hepatic function abnormal 71.22 15.16 54 9151 32627 50563292
Depressed level of consciousness 56.81 15.16 58 9147 51895 50544024
Corneal epithelium defect 46.22 15.16 11 9194 324 50595595
Anterior chamber cell 41.98 15.16 11 9194 483 50595436
Punctate keratitis 40.67 15.16 11 9194 546 50595373
Blood creatine phosphokinase increased 37.43 15.16 34 9171 26333 50569586
Joint swelling 33.61 15.16 3 9202 245283 50350636
Somnolence 32.83 15.16 81 9124 154904 50441015
Liver disorder 32.66 15.16 37 9168 37185 50558734
Purpura senile 31.95 15.16 9 9196 520 50595399
Corneal oedema 30.78 15.16 11 9194 1376 50594543
Application site injury 28.95 15.16 5 9200 26 50595893
Hyponatraemic encephalopathy 28.76 15.16 7 9198 227 50595692
Neuroleptic malignant syndrome 27.85 15.16 20 9185 11110 50584809
Bradyphrenia 27.69 15.16 16 9189 6136 50589783
Tarsal tunnel syndrome 27.32 15.16 8 9197 531 50595388
Fatigue 26.40 15.16 56 9149 707545 49888374
Hypokinesia 26.18 15.16 20 9185 12197 50583722
Alcohol interaction 26.13 15.16 11 9194 2133 50593786
Blood lactate dehydrogenase increased 25.39 15.16 24 9181 19538 50576381
Bradykinesia 25.39 15.16 13 9192 3930 50591989
Peripheral swelling 24.57 15.16 4 9201 205932 50389987
Drug intolerance 24.54 15.16 5 9200 219099 50376820
Vestibular disorder 24.21 15.16 9 9196 1260 50594659
Delusion 24.20 15.16 18 9187 10551 50585368
Dependence 24.13 15.16 10 9195 1865 50594054
Drug interaction 23.74 15.16 85 9120 199536 50396383
Postoperative delirium 23.63 15.16 5 9200 85 50595834
Application site ulcer 23.00 15.16 5 9200 97 50595822
Drug ineffective 22.84 15.16 75 9130 819258 49776661
Blepharospasm 22.77 15.16 11 9194 2937 50592982
Resorption bone increased 22.37 15.16 8 9197 1003 50594916
Syncope 21.97 15.16 54 9151 102948 50492971
Hypersensitivity 21.95 15.16 6 9199 215155 50380764
Intentional product misuse 21.67 15.16 34 9171 46700 50549219
Delirium 20.86 15.16 30 9175 38162 50557757
Intellectual disability 20.31 15.16 7 9198 787 50595132
Toxicity to various agents 19.97 15.16 84 9121 212415 50383504
Blood alkaline phosphatase increased 19.80 15.16 29 9176 37497 50558422
Swelling 19.75 15.16 6 9199 200866 50395053
Drug dependence 19.68 15.16 21 9184 19738 50576181
Hyperventilation 19.00 15.16 12 9193 5397 50590522
Hallucination, visual 19.00 15.16 19 9186 16563 50579356
Rhabdomyolysis 18.94 15.16 29 9176 38998 50556921
Aspartate aminotransferase increased 18.91 15.16 43 9162 77955 50517964
Electrocardiogram T wave inversion 18.85 15.16 10 9195 3251 50592668
Attention deficit hyperactivity disorder 18.57 15.16 9 9196 2420 50593499
Interstitial lung disease 18.45 15.16 34 9171 53142 50542777
Torsade de pointes 18.26 15.16 16 9189 11819 50584100
Drug eruption 18.26 15.16 22 9183 23584 50572335
Labelled drug-drug interaction issue 18.08 15.16 5 9200 270 50595649
Electrocardiogram QT prolonged 17.78 15.16 33 9172 51853 50544066
Serotonin syndrome 17.45 15.16 22 9183 24691 50571228
Product dose omission issue 17.17 15.16 6 9199 183832 50412087
Infusion related reaction 16.78 15.16 5 9200 169552 50426367
Abnormal behaviour 16.32 15.16 19 9186 19639 50576280
Hypoglycaemic coma 15.92 15.16 8 9197 2325 50593594
Agitation 15.90 15.16 32 9173 53352 50542567
Salivary gland cancer stage IV 15.65 15.16 3 9202 30 50595889
Restlessness 15.58 15.16 21 9184 25152 50570767
Extrasystoles 15.54 15.16 10 9195 4645 50591274
Completed suicide 15.52 15.16 56 9149 131833 50464086
Pulse absent 15.25 15.16 10 9195 4796 50591123
Arthralgia 15.25 15.16 36 9169 438666 50157253
Rheumatoid arthritis 15.20 15.16 9 9196 202541 50393378
Sinusitis 15.20 15.16 6 9199 170552 50425367

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 266.19 15.69 99 6818 10835 29556775
Drug abuse 120.74 15.69 119 6798 79764 29487846
Intentional overdose 91.13 15.69 74 6843 38454 29529156
Suicide attempt 65.22 15.69 58 6859 34052 29533558
Blood creatine phosphokinase increased 62.10 15.69 61 6856 40583 29527027
Depressed level of consciousness 57.46 15.69 56 6861 36886 29530724
Intentional self-injury 45.27 15.69 31 6886 12430 29555180
Altered state of consciousness 44.45 15.69 37 6880 19852 29547758
Neuroleptic malignant syndrome 42.37 15.69 33 6884 16115 29551495
Hepatic function abnormal 40.68 15.69 48 6869 39211 29528399
Somnolence 40.49 15.69 76 6841 93879 29473731
Overdose 38.75 15.69 68 6849 79751 29487859
Interstitial lung disease 30.39 15.69 51 6866 57667 29509943
Eye haematoma 29.80 15.69 6 6911 60 29567550
Drug dependence 29.27 15.69 30 6887 20951 29546659
Completed suicide 26.04 15.69 62 6855 90184 29477426
Loss of consciousness 25.97 15.69 55 6862 74001 29493609
Road traffic accident 24.94 15.69 24 6893 15537 29552073
Bradyphrenia 24.15 15.69 14 6903 4200 29563410
Gamma-glutamyltransferase increased 23.34 15.69 30 6887 26707 29540903
Liver disorder 22.46 15.69 30 6887 27719 29539891
Blood lactate dehydrogenase increased 22.43 15.69 25 6892 19184 29548426
Rhabdomyolysis 21.13 15.69 45 6872 60763 29506847
Alanine aminotransferase increased 18.60 15.69 47 6870 70897 29496713
Delirium 18.36 15.69 33 6884 39364 29528246
Hyporesponsive to stimuli 17.37 15.69 7 6910 944 29566666
Disseminated intravascular coagulation 16.78 15.69 22 6895 19958 29547652
Aspartate aminotransferase increased 16.10 15.69 40 6877 59685 29507925
Amnesia 16.10 15.69 23 6894 22620 29544990
Off label use 15.78 15.69 29 6888 300771 29266839

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 794.81 14.57 284 14010 29377 64455061
Drug abuse 453.02 14.57 310 13984 132064 64352374
Suicide attempt 234.56 14.57 163 14131 70844 64413594
Intentional self-injury 197.74 14.57 106 14188 28938 64455500
Intentional overdose 191.78 14.57 159 14135 89785 64394653
Overdose 177.64 14.57 197 14097 159369 64325069
Depressed level of consciousness 101.77 14.57 107 14187 81329 64403109
Loss of consciousness 93.21 14.57 138 14156 148227 64336211
Hepatic function abnormal 83.01 14.57 86 14208 64227 64420211
Blood creatine phosphokinase increased 80.47 14.57 81 14213 58477 64425961
Altered state of consciousness 78.57 14.57 66 14228 37836 64446602
Somnolence 75.68 14.57 150 14144 203495 64280943
Coma 66.09 14.57 89 14205 87526 64396912
Neuroleptic malignant syndrome 56.97 14.57 46 14248 24950 64459488
Corneal epithelium defect 49.50 14.57 14 14280 671 64483767
Anterior chamber cell 46.94 14.57 14 14280 810 64483628
Bradyphrenia 46.84 14.57 28 14266 9378 64475060
Punctate keratitis 46.27 14.57 14 14280 851 64483587
Drug dependence 43.77 14.57 45 14249 33267 64451171
Fatigue 37.61 14.57 68 14226 748662 63735776
Interstitial lung disease 37.45 14.57 73 14221 97659 64386779
Liver disorder 36.90 14.57 52 14242 53299 64431139
Joint swelling 36.50 14.57 3 14291 215379 64269059
Drug ineffective 35.71 14.57 84 14210 840163 63644275
Blood lactate dehydrogenase increased 35.24 14.57 40 14254 33038 64451400
Delirium 34.56 14.57 58 14236 69136 64415302
Rhabdomyolysis 33.32 14.57 67 14227 91659 64392779
Corneal oedema 32.65 14.57 14 14280 2329 64482109
Hypokinesia 30.52 14.57 27 14267 16569 64467869
Application site injury 28.65 14.57 5 14289 22 64484416
Completed suicide 27.98 14.57 111 14183 224303 64260135
Gamma-glutamyltransferase increased 27.40 14.57 43 14251 48467 64435971
Eye haematoma 26.44 14.57 6 14288 116 64484322
Tarsal tunnel syndrome 26.27 14.57 8 14286 497 64483941
Purpura senile 26.18 14.57 8 14286 503 64483935
Peripheral swelling 26.17 14.57 7 14287 209146 64275292
Drug eruption 26.15 14.57 36 14258 36100 64448338
Hyponatraemic encephalopathy 25.57 14.57 7 14287 297 64484141
Product dose omission issue 25.37 14.57 6 14288 194741 64289697
Decreased appetite 24.44 14.57 125 14169 281164 64203274
Heat illness 23.97 14.57 7 14287 376 64484062
Hypersensitivity 23.79 14.57 7 14287 196445 64287993
Drug interaction 23.62 14.57 149 14145 361934 64122504
Rheumatoid arthritis 23.61 14.57 4 14290 164290 64320148
Aspartate aminotransferase increased 23.52 14.57 69 14225 119719 64364719
Miosis 23.24 14.57 21 14273 13245 64471193
Hyperventilation 23.23 14.57 16 14278 6824 64477614
Delusion 23.06 14.57 24 14270 17990 64466448
Off label use 22.48 14.57 69 14225 632737 63851701
Abnormal behaviour 22.11 14.57 32 14262 33590 64450848
Electrocardiogram QT prolonged 21.96 14.57 52 14242 79396 64405042
Activation syndrome 21.69 14.57 6 14288 265 64484173
Alcohol interaction 21.65 14.57 13 14281 4388 64480050
Infusion related reaction 21.55 14.57 5 14289 164462 64319976
Confusional state 21.27 14.57 114 14180 261030 64223408
Application site ulcer 21.21 14.57 5 14289 115 64484323
Alanine aminotransferase increased 20.84 14.57 73 14221 138958 64345480
Drug intolerance 20.50 14.57 8 14286 187984 64296454
Blood alkaline phosphatase increased 20.29 14.57 41 14253 56238 64428200
Lymphocyte stimulation test positive 20.13 14.57 8 14286 1098 64483340
Pain 19.90 14.57 60 14234 553451 63930987
Resorption bone increased 19.71 14.57 8 14286 1160 64483278
Intentional product misuse 19.64 14.57 47 14247 72248 64412190
Postoperative delirium 19.34 14.57 5 14289 170 64484268
Bradykinesia 19.17 14.57 14 14280 6546 64477892
Cerebral infarction 18.64 14.57 33 14261 41011 64443427
Speech disorder 18.32 14.57 36 14258 48405 64436033
Arthralgia 18.08 14.57 45 14249 442215 64042223
Vestibular disorder 17.38 14.57 9 14285 2284 64482154
Intellectual disability 17.33 14.57 7 14287 1003 64483435
Swelling 17.17 14.57 7 14287 160211 64324227
Hypoglycaemic coma 16.92 14.57 11 14283 4263 64480175
Restlessness 16.81 14.57 31 14263 39754 64444684
Blepharospasm 16.68 14.57 10 14284 3365 64481073
Pain in extremity 16.55 14.57 26 14268 303059 64181379
Treatment failure 16.44 14.57 3 14291 116813 64367625
Cough 16.42 14.57 26 14268 302122 64182316
Hyporesponsive to stimuli 16.40 14.57 8 14286 1789 64482649
Attention deficit hyperactivity disorder 15.78 14.57 9 14285 2761 64481677
Ocular hyperaemia 15.60 14.57 22 14272 22542 64461896
Dysarthria 15.47 14.57 38 14256 59368 64425070
Arthropathy 15.22 14.57 4 14290 120963 64363475
Torsade de pointes 15.20 14.57 19 14275 17344 64467094
Labelled drug-drug interaction issue 15.11 14.57 5 14289 407 64484031
Dependence 15.03 14.57 8 14286 2147 64482291
Toxicity to various agents 14.84 14.57 134 14160 363379 64121059
Disinhibition 14.73 14.57 8 14286 2235 64482203
Fall 14.72 14.57 149 14145 416677 64067761
Suicidal ideation 14.68 14.57 40 14254 66502 64417936

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD05 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
FDA EPC N0000175694 Benzodiazepine
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Syncope contraindication 271594007
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.22 Basic
pKa2 4.62 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.70 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.88 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.11 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.70 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.22 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.16 WOMBAT-PK CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.23 WOMBAT-PK CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.85 WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.02 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.64 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.10 WOMBAT-PK CHEMBL
GABA-A receptor Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.10 IUPHAR CHEMBL
Platelet-activating factor receptor GPCR Ki 5.88 PDSP
Cytochrome P450 3A4 Enzyme Ki 4.27 WOMBAT-PK
Cholecystokinin receptor type A GPCR IC50 4.41 CHEMBL
GABA-A receptor; anion channel Ion channel Ki 9.10 CHEMBL

External reference:

IDSource
4018066 VUID
N0000146407 NUI
D00387 KEGG_DRUG
4018066 VANDF
C0040879 UMLSCUI
CHEMBL646 ChEMBL_ID
DB00897 DRUGBANK_ID
D014229 MESH_DESCRIPTOR_UI
5556 PUBCHEM_CID
7313 IUPHAR_LIGAND_ID
3409 INN_ID
1HM943223R UNII
10767 RXNORM
3103 MMSL
5618 MMSL
d00397 MMSL
001466 NDDF
111128007 SNOMEDCT_US
386984001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Halcion HUMAN PRESCRIPTION DRUG LABEL 1 0009-0017 TABLET 0.25 mg ORAL NDA 33 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 0054-4858 TABLET 0.13 mg ORAL ANDA 30 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 0054-4859 TABLET 0.25 mg ORAL ANDA 30 sections
TRIAZOLAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-236 TABLET 0.25 mg ORAL NDA authorized generic 28 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 21695-284 TABLET 0.25 mg ORAL ANDA 22 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 21695-303 TABLET 0.13 mg ORAL ANDA 22 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 43063-996 TABLET 0.25 mg ORAL ANDA 29 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 43063-996 TABLET 0.25 mg ORAL ANDA 29 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 43353-451 TABLET 0.25 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 50090-0522 TABLET 0.25 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 50090-4733 TABLET 0.25 mg ORAL ANDA 30 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 50436-3718 TABLET 0.25 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 50742-645 TABLET 0.13 mg ORAL ANDA 30 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 50742-646 TABLET 0.25 mg ORAL ANDA 30 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 55289-787 TABLET 0.25 mg ORAL NDA authorized generic 33 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 55289-787 TABLET 0.25 mg ORAL NDA authorized generic 33 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 59762-3717 TABLET 0.13 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 59762-3718 TABLET 0.25 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 63629-2956 TABLET 0.25 mg ORAL ANDA 30 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 67544-725 TABLET 0.25 mg ORAL ANDA 23 sections
Triazolam HUMAN PRESCRIPTION DRUG LABEL 1 71335-1876 TABLET 0.25 mg ORAL ANDA 30 sections